| Samuel L Ashton, MFTI | |
|
750 N Freedom Blvd, Provo, UT 84601-1677 | |
| (801) 373-4760 | |
| Not Available |
| Full Name | Samuel L Ashton |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 750 N Freedom Blvd, Provo, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144321779 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 5988945-3904 (Utah) | Primary |
| Entity Name | Wasatch Behavioral Health Special Service District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356357115 PECOS PAC ID: 2567367915 Enrollment ID: O20031129000014 |
News Archive
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
One in eight women in the United States will develop breast cancer. Of those, many will undergo surgery to remove the tumor and will require some kind of breast reconstruction afterward, often involving implants. Cancer is an elusive target, though, and malignant cells return for as many as one-fifth of women originally diagnosed, according to the American Cancer Society.
Autophagy allows cells to degrade and recycle their cellular components. Researchers at UZH have now demonstrated that the autophagy machinery in certain immune cells leads to the immune system attacking the central nervous system.
A new drug that could make it easier for doctors to diagnose multiple sclerosis in its earlier stages has been approved for its first human trials by the U.S. Food and Drug Administration.
Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samuel L Ashton, MFTI 750 N Freedom Blvd, Provo, UT 84601-1677 Ph: (801) 373-4760 | Samuel L Ashton, MFTI 750 N Freedom Blvd, Provo, UT 84601-1677 Ph: (801) 373-4760 |
News Archive
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
One in eight women in the United States will develop breast cancer. Of those, many will undergo surgery to remove the tumor and will require some kind of breast reconstruction afterward, often involving implants. Cancer is an elusive target, though, and malignant cells return for as many as one-fifth of women originally diagnosed, according to the American Cancer Society.
Autophagy allows cells to degrade and recycle their cellular components. Researchers at UZH have now demonstrated that the autophagy machinery in certain immune cells leads to the immune system attacking the central nervous system.
A new drug that could make it easier for doctors to diagnose multiple sclerosis in its earlier stages has been approved for its first human trials by the U.S. Food and Drug Administration.
Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.
› Verified 4 days ago
Dr. Shayne Anderson, PH.D. Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 262 Taylor Building, Brigham Young University, Provo, UT 84602 Phone: 801-422-6416 | |
Mr. Mark J Mauzy, MS Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 755 S 400 W, Provo, UT 84601 Phone: 801-422-7620 | |
Tabitha Nicole Webster, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 750 N Freedom Blvd, Provo, UT 84601 Phone: 801-373-4760 | |
Gary Barlow Lundberg, M.A. - LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3680 Little Rock Dr, Provo, UT 84604 Phone: 801-224-3447 Fax: 800-122-4345 | |
Mr. Adrian Kupper Baures, MFTI Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 151 S University Ave, Suite 1400, Provo, UT 84601 Phone: 801-851-7127 Fax: 801-851-7186 | |
Boone R Christianson, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3210 N Canyon Rd Ste 204, Provo, UT 84604 Phone: 385-241-1046 | |
April Knight, ALMFT Couples Therapy Medicare: Medicare Enrolled Practice Location: 750 N Freedom Blvd, Provo, UT 84601 Phone: 801-373-4760 Fax: 801-373-0639 |